Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Eberconazole→

Eberconazole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
128326-82-9
Molecular formula
C18H14Cl2N2
Molecular weight
329.2 g/mol
Drug class
Topical imidazole antifungal
Mechanism of action
As an imidazole antifungal, eberconazole is understood to inhibit fungal ergosterol biosynthesis through interference with lanosterol 14α-demethylase, disrupting fungal cell-membrane integrity; the specific molecular contribution of each pathway has not been fully characterised in the cited clinical trial.
Indications / reported uses
  • Topical treatment of dermatophytoses
  • Topical use has also been reported for cutaneous candidiasis and pityriasis; exact indications depend on the locally authorised formulation

Sources: PubMed multicentre randomised trial — Eberconazole 1% cream for dermatophytosis · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Eberconazole Environmental Risk Assessment (ERA) (the Eberconazole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.